158 related articles for article (PubMed ID: 8168116)
1. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
Weiskirch LM; Bar-Dagan Y; Mokyr MB
Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
[TBL] [Abstract][Full Text] [Related]
2. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
Gorelik L; Rubin M; Prokhorova A; Mokyr MB
J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
[TBL] [Abstract][Full Text] [Related]
3. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
Gorelik L; Prokhorova A; Mokyr MB
Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
[TBL] [Abstract][Full Text] [Related]
4. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
[TBL] [Abstract][Full Text] [Related]
5. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma.
Cook-Mills JM; Mokyr MB; Cohen RL; Perlman RL; Chambers DA
Cancer Immunol Immunother; 1995 Feb; 40(2):79-87. PubMed ID: 7882386
[TBL] [Abstract][Full Text] [Related]
6. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
[TBL] [Abstract][Full Text] [Related]
7. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.
Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB
Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031
[TBL] [Abstract][Full Text] [Related]
8. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
[TBL] [Abstract][Full Text] [Related]
9. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells.
Sojka DK; La Motte RN; Mokyr MB
Cancer Immunol Immunother; 2000 Apr; 49(1):10-22. PubMed ID: 10782862
[TBL] [Abstract][Full Text] [Related]
10. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
11. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
Takesue BY; Pyle JM; Mokyr MB
Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
[TBL] [Abstract][Full Text] [Related]
12. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Mokyr MB
Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
[TBL] [Abstract][Full Text] [Related]
13. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
14. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
Gorelik L; Mokyr MB
Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
[TBL] [Abstract][Full Text] [Related]
15. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
Takesue BY; Bartik MM; Mokyr MB
Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
[TBL] [Abstract][Full Text] [Related]
16. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
Bartik MM; Takesue BY; Mokyr MB
Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
Mokyr MB; Bartik MM; Ahn MC
Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
[TBL] [Abstract][Full Text] [Related]
18. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB
Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
[TBL] [Abstract][Full Text] [Related]
20. Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Bocian RC; Ben-Efraim S; Dray S; Mokyr MB
Cancer Immunol Immunother; 1984; 18(1):41-8. PubMed ID: 6435857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
